CorMedix Inc. Receives Positive Feedback from FDA for Neutrolin Clinical Trial Protocol for Oncology Patients BEDMINSTER, N.J.

CorMedix Inc. Receives Positive Feedback

from FDA for Neutrolin Clinical Trial Protocol for Oncology

BEDMINSTER, N.J., June 17, 2015 -- CorMedix Inc. (NYSE MKT:

CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment

of cardiac, renal and infectious disease, today announced that the U.S. Food and Drug Administration (FDA) has provided

positive feedback regarding a second pivotal clinical trial protocol. The new Phase 3 protocol is designed to assess the use of

Neutrolin as a catheter lock solution in oncology patients who require total parenteral nutrition (TPN) to support

filing of a New Drug Application with the FDA. The comments provided by the FDA should enhance the quality of the proposed study.

Neutrolin has shown antimicrobial activity against many of the

pathogens that result in catheter related bloodstream infections in the oncology community. Infections pose a significant risk

for oncology patients, many of whom require the long-term use of central venous catheters. CorMedix hopes that the use of Neutrolin

in this susceptible population will help address a critical unmet medical need. Previously, the FDA reviewed the pivotal Phase

3 clinical trial protocol to evaluate the use of Neutrolin in hemodialysis patients, and preparations are underway to initiate

the trial subject to identification of funding or strategic partnering.

"CorMedix is thankful for the valuable feedback provided

by the FDA, and we are encouraged by their continued enthusiasm and support of Neutrolin," said Randy Milby, CorMedix Chief

Executive Officer. "We are optimistic that this trial will further our efforts to bring Neutrolin to market in the United

States so that more patients can benefit from its use."

Neutrolin received QIDP and Fast Track designations earlier

this year. These designations provide CorMedix with the opportunity to meet with the FDA on a more frequent basis during the review

process, and provide eligibility for priority review of the marketing application.

CorMedix Inc. is a commercial-stage biopharmaceutical company

that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and

infectious diseases. CorMedix's first commercial product in Europe is Neutrolin , a catheter lock solution for the prevention

of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used

for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving

total parenteral nutrition, IV hydration, and/or IV medications. Plans are in progress to expand commercial distribution into

the United States, Asia, the Middle East, South America and Africa upon appropriate regulatory approval. For more information

visit www.cormedix.com.

745 Route 202-206, Suite 303, Bridgewater,

Tel: (908) 517-9500 - Fax: (908) 429-4307

Forward-Looking Statements

This press release contains forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements,

other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects,

future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that

actual results may differ materially from projections or estimates due to a variety of important factors, including: the cost,

timing and results of the planned Phase 3 trials for Neutrolin in the U.S.; obtaining regulatory approvals to conduct clinical

trials and to commercialize CorMedix's product candidates, including marketing of Neutrolin in countries other than Europe;

the risks associated with the launch of Neutrolin in new markets; CorMedix's ability to enter into, execute upon and maintain

collaborations with third parties for its development and marketing programs; CorMedix's ability to maintain its listing on the

NYSE MKT; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources; the outcome of clinical

trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix's dependence

on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; obtaining additional

financing to support CorMedix's research and development and clinical activities and operations; CorMedix's dependence on preclinical

and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations,

and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described

in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov

or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements,

and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update

these forward-looking statements, except as required by law.

745 Route 202-206, Suite 303, Bridgewater,

Tel: (908) 517-9500 - Fax: (908) 429-4307